Navigation Links
Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
Date:10/7/2009

TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has established a new Anti-Viral Research Group in its R&D organization. The new group has responsibility for coordinating, expanding and leveraging the company's multiple external collaborations already underway or planned to assess the potential utility of Peregrine's phosphatidylserine (PS)-targeting antibody platform for the prevention and treatment of a broad range of serious infectious diseases, including viral hemorrhagic fevers (VHF) and other biodefense threats, HIV, influenza, cytomegalovirus (CMV), leishmaniasis and malaria.

Peregrine's broad-spectrum PS-targeting antibodies are being assessed in anti-infective applications by more than a dozen leading research institutions. These collaborative efforts include studies assessing PS-targeting antibodies as potential therapeutics for HIV, VHF and CMV; studies assessing anti-PS antibodies as vaccines or vaccine adjuvants for the prevention of HIV and other infectious diseases; and studies of PS-targeting antibodies as potential topical microbicides against sexually transmitted diseases such as HIV and herpes viruses. Peregrine and its collaborators have already secured over $60 million in research funding to evaluate the potential of the company's PS-targeting platform in a wide range of viral infections, and Peregrine researchers believe there is significant potential for additional applications of the technology in other infectious diseases.

"We are establishing our new Anti-Viral Research Group to maximize the clinical and commercial potential represented by the increasing interest from major research institutions and private and public funding agencies in studying our PS-targeting antibody platform as a novel approach to the prevention and
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
2. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
3. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
4. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
5. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
6. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
7. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
8. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... and Chinese Medical X-ray Film Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese Medical X-Ray ... study on the current state of the Global medical ... situation. The report provides a basic overview of ...
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... ST. LOUIS , July 11, 2014 ... medical device company, announced today the positive, ... of its innovative SPiNPerc™ procedure. The SPiNPerc ... use of a percutaneous approach to biopsy ... possible.  Hospitals, patients and physicians experience positive ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... 12, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a ... today announced that a catheter,treated with a ... a 21 day study., In the study, ... in a phosphate-suffered solution along with an,untreated ...
... - GenoMed (OTC Pink,Sheets:GMED), the Next Generation Disease ... publication of a,case report of a sickle cell ... thanks to GenoMed's treatment., The patient is a ... pain pills every day to tolerate the pain,of ...
Cached Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3GenoMed Prevents Sickle Cell Pain for Over a Year 2
(Date:7/13/2014)... Micro irrigation systems are mainly utilized ... as wells as to maintain soil quality. The application ... become a dominant revenue generator for manufacturers in future. ... resource costs has led to the adoption of micro ... further caused massive demand for micro irrigation systems, as ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fuel additives ... as gasoline, diesel, jet fuel, kerosene, and so on, ... also responsible for reducing the corrosion effects caused by ... when added to any fuel, provide economies of scale ... these escalate the overall cost of the fuel products. ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 A ... attention to the cancer risks associated with power morcellators ... tell their story to federal regulators, as they presented ... U.S. Food & Drug Administration (FDA) advisory panel meeting ... According to the Rochester Democrat and Chronicle, Dr. ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
(Date:7/13/2014)... July 13, 2014 Max International ... Chris Mullin, will be the featured guest at its ... in Puerto Rico. Attendees will learn about Max’s ... in two exhibition basketball games and perform in a ... supplier of health- and energy-boosting supplements , has recently ...
Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced that ... following investor conferences,in November and December:, Lazard Capital ... 2 East 55th Street, New York Presentation: ... Annual Piper Jaffray Health Care Conference The New York ...
... blood flow , , TUESDAY, Nov. 11 (HealthDay News) -- Throw ... back and relax in the knowledge that your blood vessels ... , Nothing could be healthier for your heart, a new ... good may also be a good preventive measure for heart ...
... Nov. 11 Anthem Blue Cross and,Blue Shield in ... 239 health,insurance plans, according to the current (Nov. 17) ... Plans 2008-09. This recognition as,one of the nation,s best ... clinical care measures, member satisfaction and NCQA,accreditation., "We ...
... carry cholesterol and triglycerides throughout the body , , TUESDAY, ... particles may increase the risk of high blood pressure ... That,s the conclusion of a new study by U.S. ... the Women,s Health Study. , Lipoprotein particles carry cholesterol ...
... Minimal or Free and Best Option for Prevention;,Yet 5% Would ... Staying,Healthy., YONKERS, N.Y., Nov. 11 According to a ... to get the,flu vaccine this year, despite its being the ... long list of poor excuses,for not getting the vaccine, including ...
... Southwestern Medical Center have uncovered new insights into the "Dr. ... stem-cell maturation in the brain but, paradoxically, can also lead ... mice scheduled to appear online this week and in an ... of Sciences , UT Southwestern research teams studied the protein ...
Cached Medicine News:Health News:Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 2Health News:Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 3Health News:Joyful Music in Tune With Heart Health 2Health News:Joyful Music in Tune With Heart Health 3Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 2Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 3Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 4Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 5Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 6Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 7Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 8Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 9Health News:Lipoprotein Levels May Predict Women's Hypertension Risk 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 3Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 4Health News:Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find 2Health News:Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: